建議修訂《公司章程》《股東大會議事規則》《董事會議事規則》 並取消監事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 本公告是由本公司根據《香港上市規則》第13.51(1)條發出的。 公司謹此宣佈，董事會已於2025年8月15日決議向股東建議對《公司章程》《股東大會議事規則》及《董 事會議事規則》作出若干修訂並取消監事會。 建議修訂《公司章程》 2024年7月1日，《公司法》生效實施。中國證監會發佈《關於新<公司法>配套制度規則實施相關過渡 期安排》以及《章程指引》等相關法律、行政法規和規範性文件，並自發佈之日起生效實施。鑒於上述 法律、行政法規和規範性文件的變化，並結合實際情況，本公司建議對現行《公司章程》進行修訂。 1 建議修訂《公司章程》主要包括(1)將《公司章程》中有關「股東大會」的表述統一調整為「股東會」；(2)進 一步明確股東會、董事會決策權限及範圍；(3)刪除監事會相關章節及內容；(4)將「審核委員會」更名 為「審計委員會」，並行使 ...

Core Viewpoint - Baiyunshan (00874) reported a slight increase in revenue for the first half of 2025, but a decrease in net profit, indicating challenges in demand and competition within the industry [1] Financial Performance - The company's revenue for the first half of 2025 was approximately 41.835 billion yuan, representing a year-on-year growth of 1.93% [1] - The net profit attributable to shareholders was about 2.516 billion yuan, showing a year-on-year decrease of 1.31% [1] - Basic earnings per share were reported at 1.548 yuan, with a proposed cash dividend of 0.40 yuan per share (tax included) [1] Industry Challenges - The decline in profit compared to the previous year is primarily attributed to insufficient demand, intensified industry competition, and ongoing industry policy impacts [1] - The performance of certain business segments within the group has also experienced a downturn [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 內地個人及企業投資者通過滬港通或深港通投資香港聯交所上市股票的股東應付股息以人民幣 派發，並由本公司委託中國證券登記結算有限公司上海分公司及深圳分公司（「中登公司」）進行派 發，相關股息將於2025年9月26日（星期五）由本公司發放至中登公司，並由中登公司統一派發。 (3) 根據《中華人民共和國企業所得稅法》以及《中華人民共和國企業所得稅法實施條例》（統稱「稅 法」）的規定，自2008年1月1日起，凡中國境內企業向非居民企業股東派發股息時，需代扣代繳 企業所得稅，並以支付人為扣繳義務人。因此，本公司向2025年9月8日（星期一）名列於H股股東 名冊上的非居民企業股東派發2025年中期股息時，有義務代扣代繳10%的企業所得稅；向2025年 9月8日（星期一）名列於H股股東名冊上的居民企業股東派發2025年中期股息時，無代扣代繳企業 所得稅的義務。名列在本公司H股股東名冊上的依法在中國境內成立，或者依照外國 ...

[Important Notice](index=1&type=section&id=%E4%B8%80%E3%80%81%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) [Dividend Distribution Plan](index=1&type=section&id=1.1%20%E8%82%A1%E6%81%AF%E5%88%86%E9%85%8D%E9%A0%90%E6%A1%88) The Board resolved to distribute a cash dividend of RMB 0.40 per share (tax inclusive) to all shareholders, totaling RMB 650,316,379.60 (tax inclusive), with no bonus shares or capital reserve conversion H1 2025 Dividend Distribution Plan | Indicator | Value | | :--- | :--- | | Cash Dividend Per Share (Tax Incl.) | RMB 0.40 | | Total Share Capital (As of Jun 30, 2025) | 1,625,790,949 shares | | Total Proposed Cash Dividend (Tax Incl.) | RMB 650,316,379.60 | | Bonus Shares | None | | Capital Reserve Conversion to Share Capital | None | [Report Description and Board Statement](index=1&type=section&id=1.2%20%E5%A0%B1%E5%91%8A%E8%AA%AA%E6%98%8E%E8%88%87%E8%91%A3%E4%BA%8B%E6%9C%83%E8%81%B2%E6%98%8E) This summary is extracted from the company's H1 2025 report, with the Board, Supervisory Committee, and senior management guaranteeing its truthfulness, accuracy, and completeness; the financial report for this period is unaudited and prepared under China Accounting Standards, with the Chinese version prevailing - This interim report summary is extracted from the full 2025 interim report, investors are advised to read the full report carefully[5](index=5&type=chunk) - The Board, Supervisory Committee, and their directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of this summary and assume legal responsibility[5](index=5&type=chunk) - The Group's and the company's financial reports for this period are prepared under China Accounting Standards and are unaudited[7](index=7&type=chunk) [Board of Directors Composition](index=1&type=section&id=1.3%20%E8%91%A3%E4%BA%8B%E6%9C%83%E6%88%90%E5%93%A1%E6%A7%8B%E6%88%90) As of the announcement date, the company's Board comprises five executive directors and four independent non-executive directors, all of whom attended the 28th meeting of the Ninth Board of Directors - Board members include executive directors Li Xiaojun, Cheng Ning, Cheng Hongjin, Tang Heping, Li Hong, and independent non-executive directors Chen Yajin, Huang Min, Huang Longde, Sun Baoqing[5](index=5&type=chunk) - All directors attended the 28th meeting of the Ninth Board of Directors, with three independent non-executive directors participating via telecommunication[5](index=5&type=chunk) [Definitions](index=2&type=section&id=%E4%BA%8C%E3%80%81%E9%87%8B%E7%BE%A9) This section defines common terms used in the report, including company names, geographical areas, reporting periods, group entities, management bodies, regulatory agencies, and business-related professional terms Definitions of Key Terms | Term | Definition | | :--- | :--- | | Company/This Company/GPHL Baiyunshan | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | | Reporting Period | January 1, 2025 to June 30, 2025 | | GPHL | Guangzhou Pharmaceutical Group Co., Ltd., the company's controlling shareholder | | S2B2C | Suppliers to Business to Customers, a one-stop service system from industry to business to end-users, directly reaching individual consumers | | ERP | Enterprise Resource Planning, an information technology-based systematic management platform | | SPD | Supply Processing Distribution, a medical SPD supply chain management model | [Company Profile](index=5&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) [Company Introduction](index=5&type=section&id=3.1%20%E5%85%AC%E5%8F%B8%E7%B0%A1%E4%BB%8B) The company is listed on the Shanghai Stock Exchange (A-shares) and The Stock Exchange of Hong Kong Limited (H-shares) under the stock name 'Baiyunshan', with contact information for the Board Secretary and Securities Affairs Representative, along with registered address and website Company Listing Information | Indicator | A-shares | H-shares | | :--- | :--- | :--- | | Stock Abbreviation | Baiyunshan | Baiyunshan | | Stock Code | 600332 | 00874 | | Listing Exchange | Shanghai Stock Exchange | The Stock Exchange of Hong Kong Limited | - The company's registered and office address is No. 45 Shamian North Street, Liwan District, Guangzhou, Guangdong Province, China, and its principal place of business in Hong Kong is Room 2005, 20th Floor, Tower 2, Lippo Centre, 89 Queensway, Hong Kong[11](index=11&type=chunk) [Key Accounting Data and Financial Indicators](index=6&type=section&id=3.2%20%E4%B8%BB%E8%A6%81%E6%9C%83%E8%A8%88%E6%95%B8%E6%93%9A%E5%92%8C%E8%B2%A1%E5%8B%99%E6%8C%87%E6%A8%99) During the reporting period, the company's operating revenue increased by 1.93% year-on-year, but total profit and net profit attributable to parent company shareholders decreased by 4.30% and 1.31% respectively; net cash flow from operating activities significantly dropped by 66.79% due to lower cash collection and increased procurement payments, while net assets and total assets continued to grow Key Accounting Data (Current Period vs. Prior Period) | Indicator | Current Period (RMB Yuan) | Prior Period (RMB Yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 41,834,546,114 | 41,042,815,088 | 1.93 | | Total Profit | 3,090,416,329 | 3,229,403,377 | (4.30) | | Net Profit Attributable to Parent Company Shareholders | 2,516,140,987 | 2,549,565,302 | (1.31) | | Net Cash Flow from Operating Activities | (3,397,136,268) | (2,036,740,495) | (66.79) | Key Financial Indicators (Current Period vs. Prior Period) | Indicator | Current Period | Prior Period | YoY Change | | :--- | :--- | :--- | :--- | | Basic EPS (RMB/share) | 1.548 | 1.568 | (1.31)% | | Diluted EPS (RMB/share) | 1.548 | 1.568 | (1.31)% | | Weighted Average ROE (%) | 6.77 | 7.04 | Decrease of 0.27 percentage points | - Net cash flow from operating activities decreased by **66.79%** year-on-year, primarily due to lower cash collection and increased procurement payments[14](index=14&type=chunk) [Top Ten Shareholders' Holdings](index=8&type=section&id=3.3%20%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E6%9D%B1%E6%8C%81%E8%82%A1%E6%83%85%E6%B3%81) As of the end of the reporting period, the company had 85,550 shareholders; controlling shareholder GPHL held 45.04% of shares, and HKSCC Nominees Limited was the second largest shareholder with 13.52% - As of the end of the reporting period, the total number of shareholders was **85,550 households**[15](index=15&type=chunk) Top Ten Shareholders' Holdings | Shareholder Name | Shareholder Type | Approx. % of Total Share Capital | Number of Shares Held | | :--- | :--- | :--- | :--- | | GPHL | State-owned Legal Person | 45.04 | 732,305,103 | | HKSCC Nominees Limited | Overseas Legal Person | 13.52 | 219,783,142 | | Guangzhou Chengfa | Other | 4.16 | 67,576,183 | | China Securities Finance Corporation Limited | State-owned Legal Person | 2.91 | 47,277,962 | [Preferred Shareholder Information](index=9&type=section&id=3.4%20%E5%84%AA%E5%85%88%E8%82%A1%E8%82%A1%E6%9D%B1%E6%83%85%E6%B3%81) As of the end of the reporting period, the company had no preferred shareholders - As of the end of the reporting period, the company had no preferred shareholders[17](index=17&type=chunk) [Changes in Controlling Shareholder or Actual Controller](index=9&type=section&id=3.5%20%E6%8E%A7%E

Group 1 - The stock price of Baiyunshan is reported at 26.78 yuan as of August 13, 2025, with a slight decrease of 0.03 yuan, representing a drop of 0.11% from the previous trading day [1] - Baiyunshan's main business includes the research and manufacturing of traditional Chinese and Western medicines, chemical raw materials, biomedicine, as well as health products and medical services [1] - The company holds significant brands such as Wanglaoji and Chen Lijie, establishing an important position in the pharmaceutical industry [1] Group 2 - Former chairman Li Chuyuan and former director Zhang Chunbo of Baiyunshan and Guangzhou Pharmaceutical Group are under investigation for alleged illegal activities, including inflating drug prices and corruption in brand authorization management [1] - This case is highlighted as a significant incident within the recent anti-corruption campaign in the pharmaceutical sector [1] Group 3 - On August 13, Baiyunshan experienced a net outflow of 680,200 yuan in principal funds, with a cumulative net outflow of 7,958,900 yuan over the past five days [1]

金融界消息 截至2025年8月11日收盘，白云山（600332）报收于26.75元，上涨0.26%，换手率0.55%， 成交量7.77万手，成交金额2.07亿元。 资金流向方面，今日主力资金净流出1842.55万元，占比成交额8.88%。其中，超大单净流出2579.70万 元、占成交额12.43%，大单净流入737.15万元、占成交额3.55%，中单净流出流入1474.90万元、占成交 额7.11%，小单净流入367.66万元、占成交额1.77%。 白云山最新一期业绩显示，截至2025一季报，公司营业总收入224.73亿元、同比减少2.06%，归属净利 润18.21亿元，同比减少6.99%，扣非净利润16.75亿元，同比减少8.67%，流动比率1.542、速动比率 1.242、资产负债率50.48%。 天眼查商业履历信息显示，广州白云山医药集团股份有限公司，成立于1997年，位于广州市，是一家以 从事医药制造业为主的企业。企业注册资本162579.0949万人民币，实缴资本73230.5103万人民币。公司 法定代表人为李小军。 通过天眼查大数据分析，广州白云山医药集团股份有限公司共对外投资了57家企业，参与 ...

Core Viewpoint - The conference held on August 9 by Guangzhou Pharmaceutical Baiyunshan focused on the latest research breakthroughs of Xingqun Ertian Oil in the field of mosquito repellent and discussed the protection of traditional Chinese medicine heritage culture [1] Group 1 - The conference highlighted the advancements in mosquito repellent research related to Xingqun Ertian Oil [1] - The event included an academic discussion on the protection of intangible cultural heritage related to traditional Chinese medicine [1]

Group 1 - The company activated its emergency response mechanism promptly in response to disaster situations, assessing the needs of affected areas and quickly dispatching targeted medicines [1][2] - In Guizhou's Rongjiang and Sandu, the company completed the preparation and distribution of emergency medicines and supplies worth 500,000 yuan within 48 hours, including 2,750 boxes of Baiyunshan Cold Medicine Granules and 9,600 medical masks [1] - The company provided over 6,500 targeted medicines to Huaihua's Yuanling County in Hunan, demonstrating its commitment to disaster relief efforts [1] Group 2 - The company collaborated with national strategic partners to support flood relief efforts, donating nearly 1 million yuan worth of medicines and supplies to affected areas, military personnel, and veterans [2] - The company emphasized the use of traditional Chinese medicine to build a robust "health barrier" during the disaster response [2]

天眼查商业履历信息显示，广州白云山医药集团股份有限公司，成立于1997年，位于广州市，是一家以 从事医药制造业为主的企业。企业注册资本162579.0949万人民币，实缴资本73230.5103万人民币。公司 法定代表人为李小军。 通过天眼查大数据分析，广州白云山医药集团股份有限公司共对外投资了57家企业，参与招投标项目 491次，知识产权方面有商标信息2450条，专利信息26条，此外企业还拥有行政许可83个。 金融界消息 截至2025年8月8日收盘，白云山（600332）报收于26.68元，下跌0.07%，换手率0.41%，成 交量5.71万手，成交金额1.53亿元。 资金流向方面，今日主力资金净流出1261.69万元，占比成交额8.27%。其中，超大单净流出534.90万 元、占成交额3.51%，大单净流出726.79万元、占成交额4.76%，中单净流出流出87.10万元、占成交额 0.57%，小单净流入1348.79万元、占成交额8.84%。 白云山最新一期业绩显示，截至2025一季报，公司营业总收入224.73亿元、同比减少2.06%，归属净利 润18.21亿元，同比减少6.99%，扣非净利润16.7 ...

来源：新华社 山体滑坡发生后，广州市成立现场指挥部，迅速组织调集精锐专业力量，全力以赴做好抢险救援、伤员 救治、人员转移等各项工作。 截至8月6日17时，白云区共出动应急、消防、公安、住建、卫健、供电、城管、水务等救援力量607人 次，调集生命探测仪、液压扩张器、挖掘机等专业救援设备733台，调集11家医院救护车10车次56人参 与救治，调拨帐篷、雨衣等应急、防疫物资2200份，排查周边区域，妥善做好群众转移工作。 目前，搜救工作仍在紧张进行中。 转自：北京日报客户端 记者从广州市白云区应急管理局获悉，6日8时30分许，由于连日大雨造成山体滑坡，致大源街大源村黄 庄片区房屋受损。截至6日17时，14名被困人员中已救出7名并送医院救治，周边地区996名居民全部转 移安置。 作者: 胡拿云 王瑞平 ...